STOCKHOLM, SE / ACCESSWIRE / October 12, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, October 12, 2023 -- Promore Pharma AB (publ) today announced that the company has entered into voluntary liquidation and that the Swedish Companies Registration Office has appointed attorney Lars-Henrik Andersson as liquidator.
STOCKHOLM, SWEDEN / ACCESSWIRE / October 05, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) nnPromore Pharma AB, reg. no. 556639-6809, held an extraordinary general meeting on Thursday, 5 October 2023. The main resolutions passed at the meeting were as follows.
STOCKHOLM, SWEDEN / ACCESSWIRE / August 16, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) Promore Pharma AB (publ) today announced that the company has entered into an agreement with Erik Penser Bank to act as liquidity provider for the Promore Pharma share starting 21 August 2023. The agreement with ABG Sundal Collier ASA, that currently serves as a liquidity provider will expire at the close of the stock exchange on 18 August 2023.
STOCKHOLM, SWEDEN / ACCESSWIRE / June 27, 2023 / Promore Pharma (STO:PROMO) (FRA:8T0) Promore Pharma AB, reg. no. 556639-6809, held its AGM on Tuesday, 27 June 2023. The main resolutions passed at the meeting were as follows.
STOCKHOLM, SWEDEN / ACCESSWIRE / June 22, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) STOCKHOLM, June 22, 2023 -- Promore Pharma AB comments today that a number of measures have been taken to reduce the Company's costs, which includes the discontinuation of the ensereptide project and the termination of the Company's key personnel. The company also announces today that it has been investigating the possibilities of carrying out a reverse acquisition for some time.
STOCKHOLM, SWEDEN / ACCESSWIRE / May 25, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0) All AGM related documents are now available on the Company's website.
STOCKHOLM, SWEDEN / ACCESSWIRE / May 23, 2023 / Promore Pharma (STO:PROMO)(FRA:8T0)